Ventricular Tachycardia

3
Pipeline Programs
5
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Rhythm Pharmaceuticals
5 programs
1
DOACPhase 41 trial
ICDN/A1 trial
RegistryN/A1 trial
Single Chamber Implantable Cardioverter DefibrillatorN/A1 trial
TPD RAMWareN/A1 trial
Active Trials
NCT00279968Completed1,326Est. Jan 2006
NCT00270933Completed742Est. Dec 2005
NCT00157820Completed354Est. Oct 2005
+2 more trials
Abbott
AbbottABBOTT PARK, IL
3 programs
1
amiodarone beta blocker sotalolPhase 41 trial
AVAI: Atrial Ventricular Arrythmia IncidenceN/A1 trial
Outcomes of Functional Substrate Mapping of Ventricular TachycardiaN/A1 trial
Active Trials
NCT00832975Completed157Est. Dec 2013
NCT05708131Unknown70Est. Dec 2024
NCT00257959Completed400Est. Oct 2004
Stuart Therapeutics
1 program
1
amiodarone beta blocker sotalolPhase 4
Biotronik
BiotronikGermany - Berlin
2 programs
Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ ProtegoN/A1 trial
SD01 ICD leadN/A1 trial
Active Trials
NCT01790841Completed240Est. Apr 2016
NCT01836497Completed163Est. Sep 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rhythm PharmaceuticalsDOAC
Abbottamiodarone beta blocker sotalol
AbbottOutcomes of Functional Substrate Mapping of Ventricular Tachycardia
Rhythm PharmaceuticalsTPD RAMWare
BiotronikSD01 ICD lead
BiotronikIforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego
AbbottAVAI: Atrial Ventricular Arrythmia Incidence
Rhythm PharmaceuticalsICD
Rhythm PharmaceuticalsRegistry
Rhythm PharmaceuticalsSingle Chamber Implantable Cardioverter Defibrillator

Clinical Trials (10)

Total enrollment: 3,836 patients across 10 trials

NCT02666742Rhythm PharmaceuticalsDOAC

DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation

Start: Feb 2017Est. completion: Apr 2021246 patients
Phase 4Completed
NCT00257959Abbottamiodarone beta blocker sotalol

Optimal Pharmacological Therapy In Implantable Defibrillator Patients (OPTIC)

Start: Jan 2001Est. completion: Oct 2004400 patients
Phase 4Completed
NCT05708131AbbottOutcomes of Functional Substrate Mapping of Ventricular Tachycardia

Outcomes of Functional Substrate Mapping of Ventricular Tachycardia

Start: Jul 2022Est. completion: Dec 202470 patients
N/AUnknown
NCT03402126Rhythm PharmaceuticalsTPD RAMWare

Tachy Prediction Download Study

Start: Jan 2018Est. completion: Feb 2020138 patients
N/ACompleted
NCT01836497BiotronikSD01 ICD lead

SD01 Master Study (Safety and Efficacy Study)

Start: May 2013Est. completion: Sep 2024163 patients
N/ACompleted
NCT01790841BiotronikIforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego

DF4 Master Study (Safety and Efficacy Study)

Start: Feb 2013Est. completion: Apr 2016240 patients
N/ACompleted
NCT00832975AbbottAVAI: Atrial Ventricular Arrythmia Incidence

AVAI: Atrial Ventricular Arrythmia Incidence

Start: Dec 2008Est. completion: Dec 2013157 patients
N/ACompleted
NCT00279968Rhythm PharmaceuticalsICD

INSIGHTS ICD Registry

Start: Feb 2004Est. completion: Jan 20061,326 patients
N/ACompleted
NCT00270933Rhythm PharmaceuticalsRegistry

MAVRIC VR ICD Registry

Start: Jan 2004Est. completion: Dec 2005742 patients
N/ACompleted
NCT00157820Rhythm PharmaceuticalsSingle Chamber Implantable Cardioverter Defibrillator

DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study

Start: Nov 2000Est. completion: Oct 2005354 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space